FR3017298B1 - Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires - Google Patents

Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Info

Publication number
FR3017298B1
FR3017298B1 FR1450956A FR1450956A FR3017298B1 FR 3017298 B1 FR3017298 B1 FR 3017298B1 FR 1450956 A FR1450956 A FR 1450956A FR 1450956 A FR1450956 A FR 1450956A FR 3017298 B1 FR3017298 B1 FR 3017298B1
Authority
FR
France
Prior art keywords
conjugates
pro
drugs
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1450956A
Other languages
English (en)
French (fr)
Other versions
FR3017298A1 (fr
Inventor
Sebastien Papot
Isabelle Opalinski
Brigitte Renoux
Thibaut Legigan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
University of Poitiers
Original Assignee
Centre National de la Recherche Scientifique
University of Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1450956A priority Critical patent/FR3017298B1/fr
Application filed by Centre National de la Recherche Scientifique, University of Poitiers filed Critical Centre National de la Recherche Scientifique
Priority to LTEP20192895.9T priority patent/LT3766510T/lt
Priority to EP15709742.9A priority patent/EP3139963B1/fr
Priority to JP2016550736A priority patent/JP6721512B2/ja
Priority to EP20192895.9A priority patent/EP3766510B1/fr
Priority to CN202210334259.4A priority patent/CN114917358A/zh
Priority to DK15709742.9T priority patent/DK3139963T3/da
Priority to DK20192895.9T priority patent/DK3766510T3/da
Priority to FIEP20192895.9T priority patent/FI3766510T3/fi
Priority to CA2938501A priority patent/CA2938501C/fr
Priority to CN201580018638.0A priority patent/CN106573071A/zh
Priority to ES20192895T priority patent/ES3074632T3/es
Priority to PT201928959T priority patent/PT3766510T/pt
Priority to US15/117,069 priority patent/US10293021B2/en
Priority to ES15709742T priority patent/ES2843798T3/es
Priority to PCT/IB2015/050914 priority patent/WO2015118497A1/fr
Publication of FR3017298A1 publication Critical patent/FR3017298A1/fr
Application granted granted Critical
Publication of FR3017298B1 publication Critical patent/FR3017298B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR1450956A 2014-02-07 2014-02-07 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires Expired - Fee Related FR3017298B1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR1450956A FR3017298B1 (fr) 2014-02-07 2014-02-07 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
CN201580018638.0A CN106573071A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药
JP2016550736A JP6721512B2 (ja) 2014-02-07 2015-02-06 がん及び炎症性疾患の治療のための結合体及びプロドラッグ
EP20192895.9A EP3766510B1 (fr) 2014-02-07 2015-02-06 Conjugués et pro-drogues pour leur utilisation dans le traitement du cancer et de maladies inflammatoires
CN202210334259.4A CN114917358A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药
DK15709742.9T DK3139963T3 (da) 2014-02-07 2015-02-06 Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme
DK20192895.9T DK3766510T3 (da) 2014-02-07 2015-02-06 Konjugater og prodrugs til anvendelse ved behandling af cancer og inflammatoriske sygdomme
FIEP20192895.9T FI3766510T3 (fi) 2014-02-07 2015-02-06 Konjugaatteja ja aihiolääkkeitä käytettäviksi syövän ja tulehdussairauksien hoidossa
LTEP20192895.9T LT3766510T (lt) 2014-02-07 2015-02-06 Konjugatai ir provaistai, skirti naudoti vėžio ir uždegiminių ligų gydyme
EP15709742.9A EP3139963B1 (fr) 2014-02-07 2015-02-06 Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires
ES20192895T ES3074632T3 (es) 2014-02-07 2015-02-06 Conjugados y profármacos para su utilización en el tratamiento del cáncer y de enfermedades inflamatorias
PT201928959T PT3766510T (pt) 2014-02-07 2015-02-06 Conjugados e pr-frmacos para a sua utilizao no tratamento do cancro e de doenas inflamatrias
US15/117,069 US10293021B2 (en) 2014-02-07 2015-02-06 Conjugates and prodrugs for treating cancer and inflammatory diseases
ES15709742T ES2843798T3 (es) 2014-02-07 2015-02-06 Conjugados y profármacos para el tratamiento del cáncer y de enfermedades inflamatorias
PCT/IB2015/050914 WO2015118497A1 (fr) 2014-02-07 2015-02-06 Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires
CA2938501A CA2938501C (fr) 2014-02-07 2015-02-06 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1450956A FR3017298B1 (fr) 2014-02-07 2014-02-07 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Publications (2)

Publication Number Publication Date
FR3017298A1 FR3017298A1 (fr) 2015-08-14
FR3017298B1 true FR3017298B1 (fr) 2016-03-04

Family

ID=50829100

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1450956A Expired - Fee Related FR3017298B1 (fr) 2014-02-07 2014-02-07 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Country Status (12)

Country Link
US (1) US10293021B2 (enExample)
EP (2) EP3766510B1 (enExample)
JP (1) JP6721512B2 (enExample)
CN (2) CN106573071A (enExample)
CA (1) CA2938501C (enExample)
DK (2) DK3139963T3 (enExample)
ES (2) ES2843798T3 (enExample)
FI (1) FI3766510T3 (enExample)
FR (1) FR3017298B1 (enExample)
LT (1) LT3766510T (enExample)
PT (1) PT3766510T (enExample)
WO (1) WO2015118497A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11384104B2 (en) 2015-06-19 2022-07-12 Centurion Biopharma Corporation Delivery systems for controlled drug release
WO2017058808A1 (en) * 2015-10-02 2017-04-06 Sirenas Llc Anti-cancer compounds and conjugates thereof
ES2948846T3 (es) 2016-03-29 2023-09-20 Toray Industries Derivado peptídico y uso del mismo
US11666657B2 (en) 2017-05-16 2023-06-06 Universite De Strasbourg Protein-drug conjugates and their use in the treatment of cancers
BR112020009836A2 (pt) * 2017-11-30 2020-10-13 Centurion Biopharma Corporation pró-drogas de ligação a albumina de derivados de auristatina e
HRP20241363T1 (hr) * 2018-04-03 2024-12-20 Syndivia Konjugat citotoksičnog lijeka i oblik predlijeka navedenog konjugata
CA3139378A1 (en) 2019-05-06 2020-11-12 Seekyo New therapeutic vectors and prodrugs for treating cancers
FR3126982B1 (fr) * 2021-09-14 2023-09-15 Centre Nat Rech Scient Vecteurs ciblant la beta-d-n-acetylglucosaminidase
CN116077674B (zh) * 2022-12-26 2025-03-25 北京大学 生物分子-聚氮氧化物偶联物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
HUE035853T2 (en) * 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
FR2960153B1 (fr) * 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant

Also Published As

Publication number Publication date
PT3766510T (pt) 2026-07-17
DK3139963T3 (da) 2020-10-26
EP3139963A1 (fr) 2017-03-15
EP3139963B1 (fr) 2020-10-07
FI3766510T3 (fi) 2026-07-08
LT3766510T (lt) 2026-07-27
EP3766510A1 (fr) 2021-01-20
ES2843798T3 (es) 2021-07-20
US10293021B2 (en) 2019-05-21
JP2017506628A (ja) 2017-03-09
CN114917358A (zh) 2022-08-19
CA2938501C (fr) 2022-04-05
CN106573071A (zh) 2017-04-19
US20170095525A1 (en) 2017-04-06
DK3766510T3 (da) 2026-06-29
JP6721512B2 (ja) 2020-07-15
CA2938501A1 (fr) 2015-08-13
FR3017298A1 (fr) 2015-08-14
EP3766510B1 (fr) 2026-05-13
ES3074632T3 (es) 2026-07-22
WO2015118497A1 (fr) 2015-08-13

Similar Documents

Publication Publication Date Title
FR22C1011I2 (fr) Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies
MA49767A (fr) Conjugués de cytokine pour le traitement de maladies auto-immunes
EP3448875A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3488001A4 (en) TREATMENT OF CANCER
EP3370703A4 (en) GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES
EP3494142A4 (en) ANTI-SIGLEC-7 ANTIBODIES FOR TREATING CANCER
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
PL3169328T3 (pl) Pochodne chinoliny do leczenia chorób zapalnych
EP3285773A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
EP2983791A4 (en) METHOD AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES
EP3389645A4 (en) COMBINATIONS FOR TREATING CANCER
EP3359192A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
EP3359255A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
EP3373962A4 (en) COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCER DISEASES
MA47408A (fr) Traitement du cancer
EP3630196A4 (en) COMBINATION THERAPIES FOR TREATMENT OF CANCER
EP3490561A4 (en) COMBINATIONS FOR TREATING CANCER
EP3458454A4 (en) Novel mitochondrial decouplers for the treatment of metabolic diseases and cancer
EP3383407A4 (en) CYTARABIN CONJUGATES FOR CANCER THERAPY
EP2967062A4 (en) DESETHYLHYDROXYCHLOROQUIN FOR THE TREATMENT OF DISEASES RELATED TO INFLAMMATION
MA46361A (fr) Traitement du cancer de la prostate

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20221005